Jove
Visualize
Contact Us

Related Experiment Videos

Hypertension complicating essential thrombocythemia.

J S Bruch1, R S Stein, J A Oates

  • 1Department of Medicine, Vanderbilt University School of Medicine, Nashville.

The American Journal of the Medical Sciences
|May 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DETERMINATION OF BRADYKININ AND KALLIKREIN AS DIAGNOSTIC METHODS IN CARDIOVASCULAR DISEASE.

A listing of research in the cardiovascular field·2014
Same author

(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2.

Nature chemical biology·2011
Same author

Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Neurological picture. Fast-growing adenoid cystic carcinoma: a neurotropic malignancy.

Journal of neurology, neurosurgery, and psychiatry·2006
Same author

An aspirin responsive non-progressive chronic chorea.

Journal of neurology, neurosurgery, and psychiatry·2006
Same author

Oxygenation of arachidonic acid by cyclooxygenases generates reactive intermediates that form adducts with proteins.

Advances in experimental medicine and biology·2002
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Essential thrombocythemia (ET) can cause hypertension and kidney problems. Treating ET improved blood pressure and symptoms in two patients, highlighting the link between blood disorders and renal health.

Area of Science:

  • Hematology
  • Nephrology
  • Internal Medicine

Background:

  • Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by high platelet counts.
  • ET is associated with complications including thrombosis, hemorrhage, and platelet dysfunction.
  • Hypertension and renal complications can occur in patients with myeloproliferative disorders.

Observation:

  • Two cases of Essential thrombocythemia (ET) with moderate to severe hypertension were observed.
  • These patients also presented with renal artery stenosis and renal microvascular lesions.
  • The clinical presentation suggested a link between ET and secondary renal pathology.

Findings:

  • Treatment of the underlying Essential thrombocythemia led to a significant reduction in blood pressure.

Related Experiment Videos

  • Improvement in clinical symptoms was noted following management of the hematologic disorder.
  • This suggests a direct impact of ET on renal hemodynamics and vascular integrity.

    • Implications:

    • Managing Essential thrombocythemia may be crucial for controlling hypertension in affected patients.
    • Understanding the relationship between ET and renal complications can guide therapeutic strategies.
    • Further research into the mechanisms linking myeloproliferative neoplasms and renal vascular disease is warranted.